Literature DB >> 15646433

Effects of a somatostatin analogue in occult gastrointestinal bleeding: a case report.

G Tamagno1, R Mioni, E De Carlo, P Maffei, D Rubello, N Sicolo.   

Abstract

We describe the case of a patient with obscure gastrointestinal bleeding and anaemia, who required repeated transfusions for about 1 year. Because of the absence of a certain diagnosis and of a surgical approach indication, we established long-acting octreotide therapy, obtaining clinical stabilisation and interruption of the transfusional need. Withdrawal of long-acting somatostatin analogue therapy was associated with renewal of bleeding that was again successfully stopped by continuous i.v. somatostatin administration followed by re-establishment of the long-acting octreotide therapy. We suggested, in absence of surgical indications and when only palliative therapies are available, a therapeutic approach with long-term SMS analogues in patients with lower digestive bleeding of a known or unknown source.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646433     DOI: 10.1016/j.dld.2004.01.028

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk patients on anticoagulation therapy.

Authors:  J Molina-Infante; B Perez-Gallardo; G Gonzalez-Garcia; M Fernandez-Bermejo; J M Mateos-Rodriguez; P Robledo-Andres
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

2.  Two for the price of one: a dual treatment benefit of long-acting octreotide in occult bleeding and diuretic intractable ascites.

Authors:  Bee Leng Lee; Jeff Turner; Joanna Hurley; John Green; Neil Hawkes; Ruth Alcolado
Journal:  Frontline Gastroenterol       Date:  2011-07-26

Review 3.  Somatostatin analogs in the medical management of occult bleeding of the lower digestive tract.

Authors:  Julie Martin-Grace; Gianluca Tamagno
Journal:  Gastroenterol Res Pract       Date:  2015-03-09       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.